Berkshire Asset Management LLC PA Sells 3,428 Shares of AbbVie Inc. $ABBV

Berkshire Asset Management LLC PA reduced its position in AbbVie Inc. (NYSE:ABBV) by 0.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 380,399 shares of the company’s stock after selling 3,428 shares during the quarter. AbbVie makes up about 3.7% of Berkshire Asset Management LLC PA’s portfolio, making the stock its 3rd largest position. Berkshire Asset Management LLC PA’s holdings in AbbVie were worth $88,078,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the second quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at $39,000. Finally, Access Investment Management LLC bought a new position in AbbVie during the second quarter worth $44,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABBV has been the subject of several research analyst reports. UBS Group decreased their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Raymond James Financial set a $256.00 price objective on AbbVie in a report on Monday, November 3rd. Finally, Scotiabank initiated coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Trading Up 1.8%

Shares of AbbVie stock opened at $231.57 on Friday. The company has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The stock has a fifty day simple moving average of $223.56 and a 200 day simple moving average of $220.85. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm earned $2.16 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.